Thermo Fisher Scientific Inc. $TMO Shares Bought by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 479,144 shares of the medical research company’s stock after buying an additional 96,610 shares during the period. Thermo Fisher Scientific makes up 1.5% of OMERS ADMINISTRATION Corp’s holdings, making the stock its 19th largest position. OMERS ADMINISTRATION Corp owned about 0.13% of Thermo Fisher Scientific worth $194,274,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Mondrian Investment Partners LTD raised its position in shares of Thermo Fisher Scientific by 146.1% during the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock worth $106,738,000 after purchasing an additional 127,357 shares during the period. TIAA Trust National Association increased its stake in Thermo Fisher Scientific by 10.5% in the 2nd quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock worth $50,256,000 after purchasing an additional 11,817 shares in the last quarter. Caledonia Investments PLC raised its holdings in Thermo Fisher Scientific by 11.5% during the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after buying an additional 11,500 shares during the period. Heritage Investors Management Corp lifted its stake in Thermo Fisher Scientific by 9.6% during the second quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock valued at $22,944,000 after buying an additional 4,971 shares in the last quarter. Finally, Vontobel Holding Ltd. increased its position in shares of Thermo Fisher Scientific by 4.5% in the second quarter. Vontobel Holding Ltd. now owns 1,089,103 shares of the medical research company’s stock worth $441,588,000 after acquiring an additional 46,743 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. Argus raised their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Morgan Stanley increased their price objective on Thermo Fisher Scientific from $560.00 to $656.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 28th. Evercore ISI lifted their target price on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Finally, Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Nineteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Thermo Fisher Scientific Trading Down 0.2%

Shares of NYSE TMO opened at $591.99 on Monday. The business has a 50 day simple moving average of $548.54 and a 200 day simple moving average of $480.12. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The stock has a market cap of $222.42 billion, a price-to-earnings ratio of 34.20, a PEG ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same period in the previous year, the company earned $5.28 earnings per share. The company’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 1,058 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the sale, the vice president owned 13,087 shares of the company’s stock, valued at $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the transaction, the executive vice president directly owned 18,731 shares in the company, valued at approximately $11,238,600. This represents a 36.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 51,800 shares of company stock valued at $30,003,027. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.